Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

PURPOSE: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimens in double-hit lymphoma (DHL) and gene copy number g...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Qianwen, Chang, Yu, Li, Ling, Li, Xin, Wang, Xinhua, Wu, Jingjing, Fu, Xiaorui, Sun, Zhenchang, Yu, Hui, Zhang, Xudong, Zhou, Zhiyuan, Nan, Feifei, Li, Zhaoming, Liu, Xiyang, Zhao, Qian, Li, Yang, Zhang, Lan, Zhang, Mingzhi, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376881/
https://www.ncbi.nlm.nih.gov/pubmed/30809101
http://dx.doi.org/10.2147/CMAR.S192143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376881/
https://www.ncbi.nlm.nih.gov/pubmed/30809101
http://dx.doi.org/10.2147/CMAR.S192143

Ejemplares similares